Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α 1- plus β 3-adrenoreceptor antagonists

Jon E. Sprague, Robert E. Brutcher, Edward M. Mills, David Caden, Daniel E. Rusyniak

Research output: Contribution to journalArticle

39 Scopus citations


1. Studies were designed to examine the effects of α 1, (a 1AR)- plus β 3-adrenoreceptor (β 3AR) antagonists on 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced hyperthermia and measures of rhabdomyolysis (creatine kinase (CK)) and renal function (blood urea nitrogen (BUN) and serum creatinine (sCr)) in male Sprague-Dawley rats. 2. MDMA (40 mg kg -1, s.c.) induced a rapid and robust increase in rectal temperature, which was significantly attenuated by pretreatment with the α 1AR antagonist prazosin (100 μg kg -1, i.p.) plus the β 3AR antagonist SR59230A (5 mg kg -1, i.p.). 3. CK levels significantly increased (peaking at 4 h) after MDMA treatment and were blocked by the combination of prazosin plus SR59230A. 4. At 4 h after MDMA treatment, BUN and sCr levels were also significantly increased and could be prevented by this combination of α 1AR- plus β 3AR-antagonists. 5. The results from this study suggest that α 1AR and β 3AR play a critical role in the etiology of MDMA-mediated hyperthermia and subsequent rhabdomyolysis.

Original languageEnglish (US)
Pages (from-to)667-670
Number of pages4
JournalBritish Journal of Pharmacology
Issue number4
StatePublished - Jun 2004


  • 3,4-Methylenedioxymethamphetamine (MDMA)
  • Creatine kinase
  • Rhabdomyolysis
  • Thermogenesis
  • UCP-3

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α <sub>1</sub>- plus β <sub>3</sub>-adrenoreceptor antagonists'. Together they form a unique fingerprint.

Cite this